



Detection value of endoscopic ultrasound-guided 19G fine-needle wet-heparinized suction for pancreatic solid tumors: a randomized controlled trial

Bo Xu^{1#}, Qian Lu^{2#}, Haiyan Xu¹, Huawei Gui³, Zhuqing Peng¹, Xiangwu Ding¹

¹Department of Gastroenterology, Wuhan Fourth Hospital, Wuhan, China; ²Department of Stomatology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; ³Department of Pathology, Wuhan Fourth Hospital, Wuhan, China

Contributions: (I) Conception and design: B Xu, X Ding; (II) Administrative support: Z Peng, X Ding; (III) Provision of study materials or patients: H Xu, H Gui, Z Peng; (IV) Collection and assembly of data: H Xu, H Gui, Z Peng; (V) Data analysis and interpretation: Q Lu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Zhuqing Peng; Xiangwu Ding, Department of Gastroenterology, Wuhan Fourth Hospital, Wuhan, China.

Email: jxyxy2010@126.com; jxyxy2010@yeah.net.

Background: Conventional endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has some inevitable flaws in the detection of pancreatic solid tumors, such as an incomplete histological structure of the obtained pancreatic biopsy tissues and blood coagulation. Heparin can prevent blood coagulation, thus improving the structural integrity of the specimen. However, whether the combination of EUS-FNA and wet heparin can improve the detection of pancreatic solid tumors needs to be further explored. Hence, this study aimed to compare the EUS-FNA combined with wet heparin and the conventional EUS-FNA, and analyze the detection value of EUS-FNA combined with wet heparin for pancreatic solid tumors.

Methods: The clinical data of 52 patients with pancreatic solid tumors who had received EUS-FNA at the Wuhan Fourth Hospital from August 2019 to April 2021 were selected. Patients were divided into a heparin group and a conventional wet-suction group using a randomized number table. The total length of biopsy tissue strips, total length of white tissue core in pancreatic biopsy lesions [according to macroscopic on-site evaluation (MOSE)], total length of white tissue core in each biopsy tissue, erythrocyte contamination in the paraffin sections, and postoperative complications were compared between the groups. The receiver operating characteristic curve was used to reflect the detection value of EUS-FNA combined with wet heparin for pancreatic solid tumors.

Results: The heparin group had a longer total length of biopsy tissue strips ($P<0.05$) and total length of white tissue core ($P<0.05$) than the conventional group. There was a positive correlation between the total length of white tissue core and the total length of biopsy tissue strips in both groups (conventional wet-suction group: $r=0.470$, $P<0.05$; heparin group: $r=0.433$, $P<0.05$). The heparin group had milder erythrocyte contamination in the paraffin sections ($P<0.05$). The total length of white tissue core in the heparin group had the highest diagnostic performance, with a Youden index of 0.819 [area under the curve (AUC) =0.944].

Conclusions: Our research shows that wet-heparinized suction improves the quality of pancreatic solid tumor tissue biopsy obtained by 19G fine-needle aspiration and is a safe and efficient aspiration method in conjunction with MOSE for tissue biopsy.

Trial Registration: Chinese Clinical Trial Registry ChiCTR2300069324.

Keywords: Endoscopic ultrasound-guided fine needle aspiration; heparin; macroscopic on-site evaluation; pancreatic tumor

Submitted Nov 30, 2022. Accepted for publication Mar 30, 2023. Published online Apr 17, 2023.

doi: 10.21037/gS-22-742

View this article at: <https://dx.doi.org/10.21037/gS-22-742>

Introduction

Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is an eminent minimally invasive technique for diagnosing gastrointestinal tumors and potentially of great value in diagnosing and treating pancreatic solid tumors (1,2). However, conventional EUS-FNA has some defects, such as an incomplete histological structure of the obtained pancreatic biopsy tissues and blood coagulation, that compromise the quality of the specimen (3). There are currently multiple approaches to improve the quality of biopsy samples, such as negative micro-pressure and fan-shaped puncture, but these methods are subject to the operator's experience and skill (4-6). Wet suction can improve the biopsy specimen integrity but fails to effectively reduce blood contamination (3,7). Heparin can prevent blood coagulation by reducing the adhesion between the biopsy tissue strips and the wall of the needle tube, thus improving the structural integrity of the specimen, increasing the sample quality, and reducing blood contamination (8). Although its safety for aspiration has been fully validated, whether EUS-FNA combined with wet heparin is helpful for the detection of pancreatic solid tumors remains to be proven. Therefore, this study aimed to perform EUS-FNA using wet-heparinized suction for

patients with pancreatic solid tumors to assess the effect of heparin on improving the structural integrity of the biopsied tissue, increasing specimen quality, and reducing blood contamination (9). We used a 19G fine needle for the puncture and applied macroscopic on-site evaluation (MOSE) (10) for the specimen evaluation. MOSE could be helpful in the diagnosis of pancreatic malignancies. It is poorly studied how to improve the diagnostic efficiency of MOSE in pancreatic cancer diagnosis by improving the quality of the samples. Therefore, further exploration of this issue would be necessary. We have proposed for the first time the use of wet-heparinized suction in processing the puncture path, in combination with MOSE. We hope this would improve the diagnostic efficiency of MOSE for pancreatic cancer by improving the quality of the samples.

A larger puncture needle could obtain as many specimens as possible to facilitate the subsequent diagnosis. We aimed to assess the effectiveness of this method in improving biopsy specimen quality in pancreatic solid tumors and guiding optimum aspiration strategies. We present the following article in accordance with the STARD and CONSORT reporting checklists (available at <https://gs.amegroups.com/article/view/10.21037/gS-22-742/rc>).

Methods

Study participants

A total of 52 patients with pancreatic solid tumors admitted to the Wuhan Fourth Hospital between August 2019 and April 2021 and who agreed to receive EUS-FNA were enrolled in the current study. All patients were given detailed information about the two aspiration methods and potential complications and were assigned to two groups using a randomized number table. There were 27 patients assigned to the experimental group (heparin-based aspiration, heparin group) and 25 to the control group (conventional wet-suction group). Clinical data were collected, including patient age, gender, type of tumor, and puncture site. The study conformed to the provisions of the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Wuhan Fourth Hospital (ID: KY 2019-022-01). Participants signed informed consent.

Highlight box

Key findings

- Wet-heparinized suction in conjunction with macroscopic on-site evaluation improved the quality and aspiration efficiency of tissue biopsy for pancreatic solid tumors.

What is known, and what is new?

- EUS-FNA has some defects, such as an incomplete histological structure of the pancreatic biopsy specimen and blood coagulation. Wet-heparinized suction could improve the histological integrity of pancreatic biopsy specimens and reduce blood contamination.
- Macroscopic on-site evaluation can improve FNA efficiency.

What is the implication, and what should change now?

- Wet-heparinized suction can improve the quality and efficiency of FNA for pancreatic biopsy specimens in conjunction with macroscopic on-site evaluation, thus reducing surgical complications.

Inclusion criteria

- (I) Patients who were aged over 18.
- (II) The presence of a solid space-occupying lesion in the pancreas confirmed by imaging and laboratory testing.
- (III) A suspected diagnosis of solid pancreatic tumor.

Exclusion criteria

- (I) Concomitant with coagulation dysfunction: international normalized ratio (INR) >1.5 or blood platelet count $<8 \times 10^4 / \text{mm}^3$.
- (II) Unable to cooperate with the procedure.
- (III) Solid lesions with cystic changes in the pancreas.

Operating equipment and operator

Ultrasound mainframe: HI VISION Avius. Ultrasonic endoscope: EG-3870UTK. Fine needle: 19G SonoTipProContr puncture needle (GUS-33-21-019, Germany, Medi-Globe GmbH). All procedures were conducted by one highly qualified endoscopist who had performed more than 500 EUS-FNA procedures.

Puncture process**Conventional wet suction**

EUS was used to locate the puncture target, and the puncture was conducted without a needle core. Saline was injected into the needle cavity before each puncture with 10 mL negative pressure. Punctures were performed three times, lifting and thrusting 40–50 times each.

Wet-heparinized suction

The pre-puncture preparation was the same as the conventional wet suction, without a needle core, and 100 U/mL of heparin saline was injected into the needle cavity. The tail of the needle was connected to a negative pressure syringe (containing 5 mL of heparin solution at the same concentration with 10 mL of negative pressure). The puncture method was the same as the routine puncture, and the above operation was repeated before each puncture. Liquid-based cytology was performed after collecting the flushing fluid. The remainder of the process was the same as the conventional method.

Specimen collection and processing**Collection**

(I) A needle core was used to push the strip tissue specimen onto a transparent plate with a diameter of 10 cm (10% neutral formalin-fixed solution). The plate was shaken intermittently, and the quality of the specimen was observed by the naked

eye. (II) A 10 mL syringe was vacuumized, and the residual hemorrhagic tissues in the needle cavity were extracted onto the slide to make cell smears (3–6 smears at a time). (III) The hemorrhagic tissues within the negative pressure syringe and the flushing fluid of the needle were collected.

Processing

(I) Paraffin sections were made for hematoxylin-eosin (HE) and immunohistochemical staining. (II) The cell smears were air-dried for Pap staining. (III) The hemorrhagic tissues and flushing fluid of the needle were collected for liquid-based cytological examination (centrifugation and membrane negative pressure suction).

Data measurement and evaluation criteria

The measured value was accurate to 1 mm.

The total length of the biopsy tissue strip was measured (the length of the needle core used to push out the tissue strip completely from the needle cavity). The total length of the white part in the tissue strip (white tissue core) was measured using a metric ruler. The length of the white tissue core obtained by the first, second, and third punctures was measured respectively.

Pathological result assessment criteria

Positive: benign, malignant, or atypical cells were identified in the pancreatic tissues; negative: no benign, malignant, or atypical cells were observed in the pancreatic tissues.

Specimen integrity evaluation criteria

Great: continuous tissue strips with minimal breakages (<30% of the total length); good: partially continuous tissue strips with partial breakages (<60% of the total length); poor: discontinuous tissue strips with multiple breakages (>60% of the total length).

Specimen pathological quality assessment

Good: sufficient tissues were obtained for pathological diagnosis, and enough tissues for immunohistochemical staining if necessary; poor: insufficient tissues were obtained for pathological diagnosis. The quality was assessed by a pathologist.

Evaluation criteria of blood contamination

Great: no red blood cells/monolayer red blood cells were observed, with no accumulation; good: red blood cell accumulation was less than one high-power field; qualified: red blood cell accumulation was over one high-power field.

The pathological results were diagnosed by two senior pathologists.

Follow-up

Routine blood examination, serum amylase, and other



CONSORT 2010 flow diagram




Figure 1 The recruitment process for study participants.

indexes and clinical symptoms and signs were monitored within 48 hours of puncture to identify any complications (intrapaneatic hemorrhage, elevated serum amylase, gastrointestinal bleeding, or gastrointestinal perforation). In-hospital observation or telephone follow-up after discharge was continued for one week.

Statistical analysis

The statistical analysis was performed using SPSS (v 18.0, IBM.com). A normality test was conducted for the quantitative data using the Shapiro-Wilk test. Normally distributed quantitative data were expressed as the mean \pm standard deviation (SD), and the independent-sample *t*-test was performed for comparisons between the groups. Non-normally distributed quantitative data were expressed as M (P25, P75), and the Wilcoxon rank-sum test was performed for comparisons between the groups. The qualitative data are expressed by the number of cases. Chi-square test was used for comparison between groups, and correction for continuity chi-square test was used when 25% of the cell

frequencies were lower than 5. The Fisher exact probability method was used when the theoretical frequency was less than 5. Measurement data were expressed by percentage, and the Wilcoxon rank-sum test was applied for ranked data. A linear correlation analysis was used for normally distributed data. Receiver operating characteristic (ROC) curve was used to reflect the detection value of EUS-FNA combined with wet heparin for pancreatic solid tumors. The area under the curve (AUC) was compared to identify the optimal cut-off value. A two-sided *P* value less than 0.05 indicated a statistically significant difference.

Results

Patient characteristics

A total of 48 patients were included, with 22 in the conventional group and 26 in the heparin group. Three cases were excluded because they were unable to cooperate with the procedure, and one case contained cystic lesions (Figure 1) (Table 1).

Table 1 Baseline characteristics of the participants

Characteristics	Heparin group	Conventional group	Statistic	P value
Age (year) (mean ± SD)	60.50±10.44	59.55±12.04	t =0.294	0.770
Gender			t =0.099	0.753
Male	13	12		
Female	13	10		
Tumor site				
Pancreatic head	5	4		
Pancreatic body	12	10		
Pancreatic tail	9	8		
The longest diameter (mm) (mean ± SD)	17.35±3.50	17.95±3.34	t =-0.613	0.543
Pathological type				
PDAC	25	22		
PET	1	0		
Site of puncture				
Stomach	23	18		
Duodenum	3	4		

SD, standard deviation; PDAC, pancreatic ductal adenocarcinoma; PET, pancreatic endocrine tumor.

There were 13 males and 13 females in the heparin group (mean age: 60.50±10.44) and 12 males and 10 females in the conventional group (mean age: 59.55±12.04) (t =0.294, P=0.770). No statistically significant difference was observed in the solid tumor volumes between the two groups (t =-0.613, P=0.543). A total of seven patients received duodenum puncture, and pancreatic ductal adenocarcinoma accounted for most of the diagnosed cases (47/48, the remaining case was diagnosed with pancreatic endocrine tumor). Most of the tumors occurred in the body and tail of the pancreas (39/48).

Comparison of puncture results

The heparin group had a longer total length of tissue strips (P<0.05) and a longer total length of white tissue core (P<0.05) than the conventional group (Figure 2). The total length of white tissue core in the heparin group was greater in the first puncture than in the second or third puncture (P<0.05). The heparin group had a significantly longer total white tissue core length from the first puncture compared with the conventional group (W =545, P<0.05) (Table 2). There was a positive correlation between the total length

of white tissue core and the total length of tissue strips in the two groups (conventional wet-suction group: r =0.470, P<0.05; heparin group: r =0.433, P<0.05). The heparin group had milder erythrocyte contamination in the paraffin sections ($\chi^2=6.506$, P<0.05) (Table 3).

The heparin group had higher-quality specimens compared with the conventional group, and the difference was statistically significant (P<0.05). Taking the “good” pathological specimen quality as the gold standard for diagnostic analysis, the optimal cut-off value of the specimen total length in the heparin group was 477.50 mm, the sensitivity was 61.10%, the specificity was 100%, and the Youden index was 0.611 [AUC =0.774; 95% confidence interval (CI): 0.597–0.951; P<0.005]. The optimal cut-off value of white tissue core total length in the heparin group was 55.50 mm, the sensitivity was 94.40%, the specificity was 87.50%, and the Youden index was 0.819 (AUC =0.944; 95% CI: 0.857–1.000; P<0.05). The optimal cut-off value of the white tissue core length in the first puncture was 34.50 mm in the heparin group, the sensitivity was 66.70%, the specificity was 87.50%, and the Youden index was 0.542 (AUC =0.806; 95% CI: 0.637–0.974; P<0.05) (Figure 3).




Figure 2 The specimens obtained from the first to third puncture in the heparin group (A-C). The specimens obtained from the first to third puncture in the control group (D-F).

Table 2 Comparison of the total length of tissue strips between the two groups

Tissue strips and White tissue core	Heparin group	Conventional group	Statistic	P
Total length of tissue strips (mm) (M, P25, P75)	469.50 (458.50, 529.25)	379 (335.75, 418.75)	W =535	<0.05
Total length of white tissue core (mm) (mean ± SD)	62.23±9.92	50.55±12.05	t =3.690	<0.05
Total length of white tissue core (mm) (first puncture) (M, P25, P75)	34.50 (28.50, 42.25)	17 (14.25, 20)	W =545	<0.05
Total length of white tissue core (second puncture) (mm) (mean ± SD)	16.31±4.66	21.00±5.63	t =3.159	<0.05
Total length of white tissue core (third puncture) (mm) (M, P25, P75)	11 (9, 13)	11.50 (10, 14.75)	W =257.500	>0.05

M, median; P25, lower quartile; P75, upper quartile.

Complications

Postoperative hyperamylasemia occurred in five patients, three of whom were in the heparin group (two received intra-stomach puncture, and one received duodenum puncture). The two patients from the conventional group both received intra-stomach punctures. They all recovered after receiving conservative medical treatment. There was

no difference in the incidence of complications between the two groups ($\chi^2=0.077$, $P>0.05$) or among the different puncture sites ($\chi^2=0.132$, $P>0.05$).

Discussion

EUS-guided biopsy is the preferred method for diagnosing

Table 3 Specimen assessment

Specimen quality and BCPS	Heparin group	Conventional group	Statistic	P
Specimen integrity				
Great	3.30	1.27	W =181	<0.05
Good	36.85	26.82	W =186	<0.05
Poor	59.85	71.91	W =409.500	<0.05
SPQ			$\chi^2=3.884$	<0.05
Good	18	9		
Poor	8	13		
BCPS			$\chi^2=6.506$	<0.05
Great	8	4		
Good	13	6		
Qualified	5	12		

BCPS, blood contamination in paraffin section; SPQ, specimen pathological quality.




Figure 3 The ROC of the TLBS, the TLWC, and the LWC-F. TLBS, total length of biopsy specimen; TLWC, total length of white tissue core; LWC-F, white tissue core length in the first puncture from the heparin group; ROC, receiver operating characteristic.

pancreatic solid tumors (11).

Wet fine-needle puncture is an improved puncture technique. Sisman *et al.* (12) reported that the wet tubing wall forms a water film to prevent adhesion between the tissues and the tubing wall, which increases the amount of tissue obtained. We selected the 19G puncture needle for wet suction in this study because a puncture needle

with a thicker diameter ensures a maximum amount of specimen can be obtained to facilitate the pathological and immunohistochemical diagnosis (13). Although it is generally believed that the performance of thicker puncture needles is unsatisfactory in some specific locations, such as the duodenum (14), a recent study by de Nucci *et al.* (15) has confirmed the feasibility and accuracy of using 19G puncture needles to obtain samples from the duodenum.

Heparin (16) has previously been used in percutaneous liver puncture to increase the specimen yield by reducing blood coagulation during the puncture process. Subsequent studies (8,12) have adopted heparin for EUS-guided fine-needle liver biopsy and discovered that heparin prevented the adhesion of tissue strips to the needle tubing wall because of blood coagulation, thus increasing the amount of obtained specimen. A recent study has explored the merits of wet-heparinized pancreas biopsy (17), but there is currently no data available to explore its effect on the quality of pancreatic specimens. Our study found that the heparin group had longer pancreatic tissue strips than the conventional group ($P<0.05$), which indicated that the coagulative activity of heparin increased the sample yield in the pancreatic biopsies.

Attempts have been made for the assessment of biopsy pancreatic cancer specimens under the guidance of EUS. Rapid On-site Evaluation (ROSE) could perform real-time cytological assessment for the biopsy specimens, and could determine the number of times for FNA (18). Even so, controversies exist among the current studies about using

ROSE to improve the diagnostic performance of EUS-FNA (19). Despite the practicability of ROSE, its operation still needs the assistance of pathologists. Some researchers have proposed MOSE as an alternative that could also improve the diagnostic performance of EUS-FNA (20,21).

We also used MOSE, which can quantitatively evaluate the red and white parts of the puncture tissues, in which the white part (white tissue core) is often purer pancreatic lesion tissue (22). The total length of white tissue core in the heparin group was longer than in the control group ($P < 0.05$), suggesting that using heparin may increase the amount of white tissue core collected. Meanwhile, the specimen integrity in the heparin group was better than in the control group, which is essential for accurate pathological diagnosis. Kaneko *et al.* measured the length of the white tissue core by manual cutting and linear arrangement (23). However, this method potentially results in a large amount of tissue loss and compromises the integrity of the tissue strip, so we chose not to cut the specimen to perform direct measurement in an effort to guarantee histological integrity. The heparin group had more “great” and “good” specimen integrity categories than the control group ($P < 0.05$). In summary, wet-heparinized suction improved the extraction of pancreatic white tissue core more effectively than the conventional wet-suction method (19). With the deepening exploration by recent studies, the quality of the EUS biopsy specimens has been significantly improved. The pathological diagnosis of the specimens has shifted from cytology to histology, and is now changing to genetics. Several studies perform Next Generation Sequencing (NGS) for endoscopic ultrasound-guided tissue acquisition (EUS-TA), use genetic analyses to guide the clinical diagnosis, and construct clinical models to guide the treatment (24,25). These make it possible to conduct the Precision Medicine.

Diagnostic analysis of the heparin group showed that the total length of the biopsy specimen, total length of white tissue core, and the white tissue core length in the first puncture were associated with “good” pathological quality. A comparison of the AUC of the three variables indicated that the total length of white tissue core had the largest area under the curve. If the total length of white tissue core obtained by wet-heparinized suction reached 55.50 mm (sensitivity 94.40%, specificity 87.50%), the biopsy specimen was considered great quality. We found that in most cases, the total length of white tissue core reached above the optimal cut-off value after the second puncture, indicating that wet-heparinized suction might help to reduce the number of punctures needed, which in turn could reduce the incidence

of related complications.

Severe fibrosis in the pancreatic peritumoral tissues can cause the white tissue strips to mingle with segmental fibrotic tissues (10,17,23), leading to bias in the MOSE. Therefore, additional laboratory diagnosis is essential. There were 45 cases that were directly diagnosed in this study via paraffin section, and the remaining three cases (two in the conventional group and one in the heparin group) were subsequently diagnosed by cytological smear and immunohistochemistry.

Liquid-based cytology is an effective complement to FNA, with the ability to collect and concentrate more tumor cells and reduce blood contamination. Sekita-Hatakeyama *et al.* (26) performed NGS for liquid-based cytological specimens to assess the mutations of KRAS, TP53, CDKN2A, SMAD4, and PIK3CA, which could improve the diagnostic efficiency of FNA for pancreatic tumors. The PDAC protein found by Souche *et al.* (27) in liquid-based cytological specimens could be a potential biomarker for pancreatic tumors.

The cytological images from the paraffin sections of the diagnosed cases were all positive, which suggests that laboratory examination might be more sensitive in positive cases (28). There was very little erythrocyte contamination in the heparin group ($P < 0.05$), supporting the previous speculation that heparin might reduce the hemagglutination in the puncture tissue strip. Heparin processing of the puncture specimens did not interfere with the cytological or immunohistochemical detection, which is consistent with the conclusion made by Diehl (29).

Hyperamylasemia occurred in five patients but returned to normal after 1–2 days of medical treatment. The remaining patients had no related complications. There was no significant difference in the incidence of complications between the groups or among the different puncture sites ($P < 0.05$). The follow-up was extended to March 2023 for all the participants. There were 5 participants (2 in the heparin group and 3 in the control group) who had lost to follow-up. Among the remaining 43 patients, only 2 are still alive after receiving surgery and conventional treatments, and the other patients had died. Their survival time ranged from 3 months to 5 months. All of these patients reported no relevant adverse events after receiving the biopsy. This demonstrates that heparin is safe for pancreatic puncture (30,31).

In this study, we made the following observations: (I) heparin can increase the total length of pancreatic white tissue core specimens, improve histological integrity, reduce blood contamination, and facilitate pathological diagnosis.

(II) The use of MOSE for the total length of pancreatic white tissue core and specimen integrity evaluation is an important reference index for wet-heparinized suction strategies for pancreatic solid tumors. It has certain merits in reducing the number of unnecessary punctures and the risk of complications. (III) Cytological and immunohistochemical detection of the puncture specimens is an essential adjunct and supplement for pathological diagnosis after FNA and provides evidential support for the follow-up treatment of pancreatic tumors. (IV) The use of heparin is safe and feasible in pancreatic EUS-FNA.

The main limitation of this study was the small number of cases included, in the future, randomized controlled trials with larger sample sizes will be needed. Additionally, the efficacy of using different puncture needle sizes and tubing diameters when performing EUS-FNA remains to be elucidated.

Conclusions

This study has demonstrated that wet-heparinized suction improved the quality of biopsy specimens obtained by 19G fine-needle aspiration for pancreatic solid tumors, with considerable safety. MOSE of biopsy specimens is helpful for improving puncture efficiency and reducing the risk of related complications.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the STARD and CONSORT reporting checklists. Available at <https://gs.amegroups.com/article/view/10.21037/gc-22-742/rc>

Trial Protocol: Available at <https://gs.amegroups.com/article/view/10.21037/gc-22-742/tp>

Data Sharing Statement: Available at <https://gs.amegroups.com/article/view/10.21037/gc-22-742/dss>

Peer Review File: Available at <https://gs.amegroups.com/article/view/10.21037/gc-22-742/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://gs.amegroups.com>).

[com/article/view/10.21037/gc-22-742/coif](https://gs.amegroups.com/article/view/10.21037/gc-22-742/coif)). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study conformed to the provisions of the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Wuhan Fourth Hospital (ID: KY 2019-022-01). Participants signed informed consent.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Jeon TY, Moon SH, Kim JH, et al. Diagnostic Performance of EUS-Guided Sampling in Indeterminate Radiological Diagnosis of Pancreatic Disease and Intra-Abdominal Lymphadenopathy. *J Clin Med* 2021;10:3850.
2. He MJ, Chen TY, Liu XY, et al. Utility of endoscopic ultrasound-guided fine-needle aspiration in pancreatic cancer patients who failed to obtain a pathological diagnosis in surgical exploration. *Gland Surg* 2022;11:426-31.
3. Wang Y, Wang RH, Ding Z, et al. Wet- versus dry-suction techniques for endoscopic ultrasound-guided fine-needle aspiration of solid lesions: a multicenter randomized controlled trial. *Endoscopy* 2020;52:995-1003.
4. Del Vecchio Blanco G, Palmieri G, Giannarelli D, et al. Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. *Scand J Gastroenterol* 2021;56:498-504.
5. Chen TY, Cao JW, Jin C, et al. Comparison of specimen quality among the standard suction, slow-pull, and wet suction techniques for EUS-FNA: A multicenter, prospective, randomized controlled trial. *Endosc Ultrasound* 2022;11:393-400.
6. Polkowski M, Jenssen C, Kaye P, et al. Technical aspects

- of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline - March 2017. *Endoscopy* 2017;49:989-1006.
7. Chen D, Ren Y, Chen S, et al. The Wet Suction Technique Enhances the Diagnostic Efficacy and Aspirate Quality of EUS-FNA for Solid Lesions: A Multicenter Retrospective Study in China. *J Clin Gastroenterol* 2023;57:417-22.
 8. Mok SRS, Diehl DL, Johal AS, et al. A prospective pilot comparison of wet and dry heparinized suction for EUS-guided liver biopsy (with videos). *Gastrointest Endosc* 2018;88:919-25.
 9. Diehl DL, Mok SRS, Khara HS, et al. Heparin priming of EUS-FNA needles does not adversely affect tissue cytology or immunohistochemical staining. *Endosc Int Open* 2018;6:E356-62.
 10. Mohan BP, Madhu D, Reddy N, et al. Diagnostic accuracy of EUS-guided fine-needle biopsy sampling by macroscopic on-site evaluation: a systematic review and meta-analysis. *Gastrointest Endosc* 2022;96:909-17.e11.
 11. Capurso G, Archibugi L, Petrone MC, et al. Slow-pull compared to suction technique for EUS-guided sampling of pancreatic solid lesions: a meta-analysis of randomized controlled trials. *Endosc Int Open* 2020;8:E636-43.
 12. Sisman G, Barbur E, Saka D, et al. Endoscopic ultrasound-guided liver biopsy using a 20-gauge fine needle biopsy needle with the wet-heparinized suction technique. *Eur J Gastroenterol Hepatol* 2020;32:1470-4.
 13. Patel HK, Saxena R, Rush N, et al. A Comparative Study of 22G versus 19G Needles for EUS-Guided Biopsies for Parenchymal Liver Disease: Are Thinner Needles Better? *Dig Dis Sci* 2021;66:238-46.
 14. Ginès A, Fusaroli P, Sendino O, et al. Performance of a new flexible 19 G EUS needle in pancreatic solid lesions located in the head and uncinate process: A prospective multicenter study. *Endosc Int Open* 2021;9:E1269-75.
 15. de Nucci G, Petrone MC, Imperatore N, et al. Feasibility and Accuracy of Transduodenal Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Solid Lesions Using a 19-Gauge Flexible Needle: A Multicenter Study. *Clin Endosc* 2021;54:229-35.
 16. Saraireh H, Abdelfattah T, Hassouneh R, et al. "Wet Heparin" and "Wet Saline" EUS-Guided Liver Biopsy Techniques Both Provide High Rates of Specimen Adequacy for Benign Parenchymal Liver Disease. *Dig Dis Sci* 2022;67:5256-61.
 17. Antkowiak R, Bialecki J, Chabowski M, et al. Treatment of Microcirculatory Disturbances in Acute Pancreatitis: Where Are We Now? *Pancreas* 2022;51:415-21.
 18. de Moura DTH, McCarty TR, Jirapinyo P, et al. Evaluation of endoscopic ultrasound fine-needle aspiration versus fine-needle biopsy and impact of rapid on-site evaluation for pancreatic masses. *Endosc Int Open* 2020;8:E738-47.
 19. Crinò SF, Di Mitri R, Nguyen NQ, et al. Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. *Gastroenterology* 2021;161:899-909.e5.
 20. Mangiavillano B, Crinò SF, Facciorusso A, et al. Endoscopic ultrasound-guided fine-needle biopsy with or without macroscopic on-site evaluation: a randomized controlled noninferiority trial. *Endoscopy* 2023;55:129-37.
 21. So H, Seo DW, Hwang JS, et al. Macroscopic on-site evaluation after EUS-guided fine needle biopsy may replace rapid on-site evaluation. *Endosc Ultrasound* 2021;10:111-5.
 22. Ishiwatari H, Sato J, Fujie S, et al. Gross visual inspection by endosonographers during endoscopic ultrasound-guided fine needle aspiration. *Pancreatology* 2019;19:191-5.
 23. Kaneko J, Ishiwatari H, Sasaki K, et al. Macroscopic on-site evaluation of biopsy specimens for accurate pathological diagnosis during EUS-guided fine needle biopsy using 22-G Franseen needle. *Endosc Ultrasound* 2020;9:385-91.
 24. Ashida R, Kitano M. Endoscopic ultrasound-guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine. *Dig Endosc* 2022;34:1329-39.
 25. Tong T, Zhang C, Li J, et al. Preclinical models derived from endoscopic ultrasound-guided tissue acquisition for individualized treatment of pancreatic ductal adenocarcinoma. *Front Med (Lausanne)* 2023;9:934974.
 26. Sekita-Hatakeyama Y, Fujii T, Nishikawa T, et al. Evaluation and diagnostic value of next-generation sequencing analysis of residual liquid-based cytology specimens of pancreatic masses. *Cancer Cytopathol* 2022;130:202-14.
 27. Souche R, Tosato G, Rivière B, et al. Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples. *Endoscopy* 2022;54:503-8.
 28. Whittle MC, Hingorani SR. Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets. *Gastroenterology* 2019;156:2085-96.
 29. Diehl DL. Top tips regarding EUS-guided liver biopsy.

- Gastrointest Endosc 2022;95:368-71.
30. Du C, Chai N, Linghu E. The diagnostic value of EUS-guided fine-needle aspiration/biopsy for solid pancreatic lesions: contrast-enhanced versus conventional EUS. *Gastrointest Endosc* 2021;94:200-1.
31. Stigliano S, Crescenzi A, Taffon C, et al. Role of

fluorescence confocal microscopy for rapid evaluation of EUS fine-needle biopsy sampling in pancreatic solid lesions. *Gastrointest Endosc* 2021;94:562-8.e1.

(English Language Editor: D. Fitzgerald)

Cite this article as: Xu B, Lu Q, Xu H, Gui H, Peng Z, Ding X. Detection value of endoscopic ultrasound-guided 19G fine-needle wet-heparinized suction for pancreatic solid tumors: a randomized controlled trial. *Gland Surg* 2023;12(4):442-452. doi: 10.21037/gs-22-742